OncoCyte Corporation
OCX
$3.44
$0.051.48%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.88M | 709.00K | 1.02M | 1.38M | 1.50M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.88M | 709.00K | 1.02M | 1.38M | 1.50M |
| Cost of Revenue | 1.20M | 736.00K | 852.00K | 989.00K | 1.00M |
| Gross Profit | 685.00K | -27.00K | 171.00K | 393.00K | 501.00K |
| SG&A Expenses | 14.15M | 12.78M | 12.35M | 12.95M | 13.54M |
| Depreciation & Amortization | 88.00K | 88.00K | 88.00K | 88.00K | 88.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.13M | 23.59M | 22.66M | 23.21M | 23.77M |
| Operating Income | -23.25M | -22.88M | -21.63M | -21.83M | -22.27M |
| Income Before Tax | -60.66M | -43.14M | -36.14M | -39.94M | -24.86M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -60.66 | -43.14 | -36.14 | -39.94 | -24.86 |
| Earnings from Discontinued Operations | -- | 0.00 | 0.00 | 0.00 | -2.93M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -60.66M | -43.14M | -36.14M | -39.94M | -27.78M |
| EBIT | -23.25M | -22.88M | -21.63M | -21.83M | -22.27M |
| EBITDA | -21.68M | -21.56M | -20.22M | -20.29M | -20.59M |
| EPS Basic | -4.40 | -4.43 | -4.26 | -4.97 | -3.51 |
| Normalized Basic EPS | -1.18 | -1.35 | -1.44 | -1.62 | -1.85 |
| EPS Diluted | -4.40 | -4.43 | -4.26 | -4.97 | -3.51 |
| Normalized Diluted EPS | -1.18 | -1.35 | -1.44 | -1.62 | -1.85 |
| Average Basic Shares Outstanding | 52.23M | 43.11M | 37.66M | 32.88M | 30.57M |
| Average Diluted Shares Outstanding | 52.23M | 43.11M | 37.66M | 32.88M | 30.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |